Use of Fluorescence Imaging in Combination with Patent Blue Dye versus Patent Blue Dye Alone in Sentinel Lymph Node Biopsy in Breast Cancer
- PMID: 25320623
- PMCID: PMC4197355
- DOI: 10.4048/jbc.2014.17.3.250
Use of Fluorescence Imaging in Combination with Patent Blue Dye versus Patent Blue Dye Alone in Sentinel Lymph Node Biopsy in Breast Cancer
Abstract
Purpose: Near-infrared fluorescence imaging with indocyanine green (ICG) has the potential to improve sentinel lymph node (SLN) mapping in breast cancer. In this clinical trial, we compared the potential value of ICG combined with blue dye with that of blue dye alone for detecting SLNs.
Methods: Patients undergoing SLN biopsy (SLNB) between November 2010 and November 2013 were included. Up to December 2011, SLNs were detected by using patent blue (PB) alone, and since January 2012, by using PB in combination with ICG. The patients were divided into the following two groups: group A (ICG-PB; n=96) and group B (PB; n=73), and SLN detection parameters were compared between the groups. All patients underwent level I and II axillary dissections after SLNB.
Results: In group A, the SLN detection rate was 96.9% (93/96), the accuracy of detection was 98.9% (92/93), and the false-negative rate (FNR) was 3.4% (1/29). In group B, the SLN detection rate was 84.9% (62/73), the accuracy of detection was 96.8% (60/62), and the FNR was 11.1% (2/18). The ICG-PB group showed significantly superior results compared to the PB group for SLN detection (p=0.005) and a greatly improved FNR.
Conclusion: The combined fluorescence and blue dye-based tracer technique was superior to the use of blue dye alone for identifying SLNs, and for predicting axillary lymph node status in patients with breast cancer; in addition, the combined technique had reduced false-negative results.
Keywords: Breast neoplasms; Indocyanine green; Optical imaging; Patent blue dye; Sentinel lymph node biopsy.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures

Similar articles
-
Indocyanine Green Fluorescence Versus Blue Dye or Radioisotope Regarding Detection Rate of Sentinel Lymph Node Biopsy and Nodes Removed in Breast Cancer: A Systematic Review and Meta-Analysis.Asian Pac J Cancer Prev. 2020 May 1;21(5):1187-1195. doi: 10.31557/APJCP.2020.21.5.1187. Asian Pac J Cancer Prev. 2020. PMID: 32458621 Free PMC article.
-
Axillary lymph node recurrence after sentinel lymph node biopsy performed using a combination of indocyanine green fluorescence and the blue dye method in early breast cancer.Breast Cancer. 2016 Mar;23(2):295-300. doi: 10.1007/s12282-014-0573-8. Epub 2014 Oct 28. Breast Cancer. 2016. PMID: 25348937
-
Evaluation of the benefit of using blue dye in addition to indocyanine green fluorescence for sentinel lymph node biopsy in patients with breast cancer.World J Surg Oncol. 2014 Sep 20;12:290. doi: 10.1186/1477-7819-12-290. World J Surg Oncol. 2014. PMID: 25239029 Free PMC article.
-
Breast cancer sentinel lymph node mapping using near-infrared guided indocyanine green in comparison with blue dye.Tumour Biol. 2014 Apr;35(4):3073-8. doi: 10.1007/s13277-013-1399-2. Epub 2013 Dec 5. Tumour Biol. 2014. PMID: 24307620 Clinical Trial.
-
Detection of sentinel lymph node in vulvar cancer using 99mTc-labeled colloid lymphoscintigraphy, blue dye, and indocyanine-green fluorescence: a meta-analysis of studies published in 2010-2020.Arch Gynecol Obstet. 2023 Jun;307(6):1677-1686. doi: 10.1007/s00404-022-06605-1. Epub 2022 May 24. Arch Gynecol Obstet. 2023. PMID: 35608701 Review.
Cited by
-
Comparisons of ICG-fluorescence with conventional tracers in sentinel lymph node biopsy for patients with early-stage breast cancer: A meta-analysis.Oncol Lett. 2021 Feb;21(2):114. doi: 10.3892/ol.2020.12375. Epub 2020 Dec 15. Oncol Lett. 2021. PMID: 33376546 Free PMC article.
-
Identification and preservation of stained non-sentinel lymph nodes in breast cancer.Oncol Lett. 2020 Dec;20(6):373. doi: 10.3892/ol.2020.12236. Epub 2020 Oct 21. Oncol Lett. 2020. PMID: 33154771 Free PMC article.
-
Determining Accurate Dye Combinations for Sentinel Lymph Node Detection: A Systematic Review.Plast Reconstr Surg Glob Open. 2024 Feb 8;12(2):e5598. doi: 10.1097/GOX.0000000000005598. eCollection 2024 Feb. Plast Reconstr Surg Glob Open. 2024. PMID: 38333031 Free PMC article.
-
Indocyanine Green Fluorescence Versus Blue Dye or Radioisotope Regarding Detection Rate of Sentinel Lymph Node Biopsy and Nodes Removed in Breast Cancer: A Systematic Review and Meta-Analysis.Asian Pac J Cancer Prev. 2020 May 1;21(5):1187-1195. doi: 10.31557/APJCP.2020.21.5.1187. Asian Pac J Cancer Prev. 2020. PMID: 32458621 Free PMC article.
-
Use of indocyanine green and the HyperEye system for detecting sentinel lymph nodes in breast cancer within a population of European patients: a pilot study.World J Surg Oncol. 2016 Dec 1;14(1):299. doi: 10.1186/s12957-016-1060-9. World J Surg Oncol. 2016. PMID: 27905950 Free PMC article.
References
-
- Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006;98:599–609. - PubMed
-
- Julian TB, Krag D, Brown A, Anderson S, Harlow S, Ashikaga T, et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinical node negative breast cancer patients. Breast Cancer Res Treat. 2004;88(Suppl):S511–S512. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources